Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Posted on by sHq_LoGiNz

Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.